Fulcrum Therapeutics(FULC)
Focus: Fulcrum Therapeutics is a Cambridge-based biotech focused on unlocking gene control mechanisms to develop small molecule therapies for rare diseases, hematology, and infectious diseases. The company is publicly traded (NASDAQ: FULC) with an 79% R&D intensity profile.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$150M
Open Jobs
0
About Fulcrum Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Fulcrum Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$80M
Pipeline & Clinical Trials
FTX-6058/placebo oral capsule
Healthy Adult SubjectsClinical Trials (1)
NCT04586985Safety, Tolerability and Pharmacokinetics of FTX-6058
Phase 1Help build intelligence for Fulcrum Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.